Vera Therapeutics Exciting Updates on Upcoming Conferences

Vera Therapeutics to Showcase Developments at Investor Conferences

Vera Therapeutics, Inc. (Nasdaq: VERA), a pioneering biotechnology firm based in Brisbane, California, focuses on developing groundbreaking treatments for serious immunological diseases. With a commitment to improving patient care, the company's management announced their participation in upcoming investor conferences, providing a platform for sharing insights and advancements in their innovative therapies.

Details of the Upcoming Conferences

Guggenheim Securities Healthcare Innovation Conference

This conference will feature a fireside chat format, complemented by one-on-one meetings. Attendees can access the webcast for live streaming of the presentation. The event is set for November 13, and will occur at 9:30 AM EST in Boston.

7th Annual Evercore ISI HealthCONx Conference

Set to take place on December 5, starting at 7:55 AM EST, this conference is another opportunity for Vera Therapeutics to showcase its pioneering efforts. The format includes a fireside chat and one-on-one meetings. Interested parties can also access the webcast to stay informed about Vera’s latest advancements and insights into their therapeutic approaches.

Accessing Recorded Webcasts

For those unable to attend live, Vera Therapeutics will provide a replay of the webcasts for 90 days after the events. Interested individuals can find these recorded sessions in the “Investor Calendar” section of the company's website, allowing stakeholders to catch up on the discussions and data shared during the conferences.

About Vera Therapeutics

Vera Therapeutics is not just a company; it is a heart and soul dedicated to addressing the challenges posed by serious immunological diseases. Their mission revolves around developing transformative treatments that directly target the root causes of these diseases, thereby improving the quality of life for patients. Among their leading products, atacicept stands out. It is a fusion protein that patients can self-administer weekly through subcutaneous injection. This innovative treatment effectively inhibits both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), both of which play critical roles in stimulating the production of autoantibodies associated with autoimmune disorders like IgAN and lupus nephritis.

Moreover, Vera Therapeutics is actively exploring additional diseases where reducing autoantibodies by using atacicept could yield significant health benefits. The company is also making strides with MAU868, a monoclonal antibody developed to neutralize BK virus (BKV) infections, particularly relevant for kidney transplant patients where BKV can pose severe risks.

Vera holds complete global developmental and commercial rights to both atacicept and MAU868, reflecting its commitment to maintaining control over its innovations and ensuring that these critical therapies reach those in need.

Contact Information

For more insights or inquiries, interested parties can reach out to the Investor Contact:

Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Alternatively, media inquiries can be directed to:

Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com

Frequently Asked Questions

What is Vera Therapeutics focused on?

Vera Therapeutics concentrates on developing transformative treatments for serious immunological diseases.

When will the Guggenheim Securities Healthcare Innovation Conference take place?

The conference is scheduled for November 13 at 9:30 AM EST in Boston.

Can I watch the conference presentations if I miss them live?

Yes, the webcasts will be accessible for 90 days after the events.

What are Vera Therapeutics' leading product candidates?

Vera's lead candidates include atacicept for autoimmune diseases and MAU868 for BK virus infections.

Who can I contact for more information about Vera Therapeutics?

For investor inquiries, contact Joyce Allaire; for media inquiries, reach out to Madelin Hawtin.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.